Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMO4S6T)

Drug Name
PF-03814735 Drug Info
Synonyms
PF-03814735; 942490-07-5; PF 03814735; PF-3814735; PF03814735; Kinome_1769; MLS006010949; CHEMBL1983111; SB19308; NCGC00389594-01; KB-74441; SMR004703046; BCP0726000114; J3.628.238J; N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide; N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide
Cross-matching ID
PubChem CID
51346455
ChEBI ID
CHEMBL4289017
CAS Number
CAS 942487-16-3
TTD Drug ID
D0H7AC

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Porphyrin and chlorophyll metabolism 2.25 0.00e+0 23/43 (53.49%) UGT2B15;CP;UGT2B17;...
Mineral absorption 1.98 1.20e-2 48/60 (80%) MT1M;SLC30A1;MT1X;...
Spliceosome -1.70 4.22e-2 101/150 (67.33%) SMNDC1;SF3B4;DHX38;...
Progesterone-mediated oocyte maturation -1.74 2.87e-2 75/100 (75%) MAPK10;AURKA;MAD1L1;...
Homologous recombination -1.84 6.70e-3 35/41 (85.37%) RAD54L;POLD1;RPA2;...
Mismatch repair -1.91 4.82e-3 22/23 (95.65%) RFC2;RFC4;POLD1;...
Fanconi anemia pathway -1.95 2.01e-3 36/54 (66.67%) TOP3A;MLH1;TELO2;...
Glycosaminoglycan biosynthesis -1.96 0.00e+0 40/58 (68.97%) EXTL1;NDST4;CHST4;...
Cell cycle -2.16 0.00e+0 110/124 (88.71%) CHEK1;TTK;ESPL1;...
DNA replication -2.67 0.00e+0 34/36 (94.44%) MCM6;MCM5;RFC2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 3.33uM 24H